Three Questions Biopharma Companies Must Ask When Building A Cell And Gene Commercialization Strategy

Breakthroughs in cell and gene therapy (CGT) are accelerating rapidly with more therapies entering the market every year, but the commercialization of these innovations is highly complex. Navigating an evolving regulatory landscape and demonstrating enough value to manage payer reimbursement approval can extend commercialization timelines and prevent patients in need from receiving timely treatment.

Sponsors must develop a commercialization strategy early in their planning to ensure success at launch and beyond. Decisions made during preclinical or Phase 1 studies can have a major impact on product success. Focusing on overcoming obstacles relating to patient support and services, supply chain, and market access can help sponsors understand if there is a commercially viable opportunity for the therapy and determine the commercialization strategy with the highest potential for success.

Learn how aligning with the right partner from the start and leveraging integrated solutions gives access to crucial know-how and ensures the patient receives the most seamless, accessible treatment option available.